We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort

This study has been withdrawn prior to enrollment.
(Lack of funding, PI left the institution, poor enrollment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01565512
First Posted: March 28, 2012
Last Update Posted: March 5, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Columbia University
March 26, 2012
March 28, 2012
March 5, 2015
November 2011
July 2014   (Final data collection date for primary outcome measure)
Prevalence of pain/discomfort [ Time Frame: postoperative ]
pain/discomfort [ Time Frame: postoperative ]
Complete list of historical versions of study NCT01565512 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort
Randomized Trial to Determine the Effect of Dorsal Penile Block on Post-Robotic Prostatectomy Foley Discomfort
The indwelling urethral foley is a major source of discomfort following radical prostatectomy. Our hypothesis is that intra-operative dorsal penile nerve block with bupivacaine may decrease immediate post-operative foley discomfort.
Patients undergoing robot-assisted radical prostatectomy (RARP) will be randomized in a double-blind placebo controlled manner to undergo penile ring block injection at the time of skin incision closure. A visual analog scale (VAS) based questionnaire including newly developed foley discomfort scores will be administered at various time points post-operatively.
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Prostate Cancer
  • Robotic Prostatectomy
  • Foley Catheter Discomfort
  • Drug: Bupivacaine
    A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
  • Drug: Saline
    A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
  • Placebo Comparator: saline injection
    saline injection
    Intervention: Drug: Saline
  • Active Comparator: Bupivacaine injection
    penile block with bupivacaine
    Intervention: Drug: Bupivacaine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
July 2014
July 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age 40 years and above,
  • diagnosis of prostate cancer,
  • electing to undergo robot-assisted radical prostatectomy

Exclusion Criteria:

  • allergy to bupivacaine or amide-type local anesthetics,
  • chronic pain condition,
  • recently or currently on narcotics,
  • genital abnormalities
Sexes Eligible for Study: Male
40 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01565512
AAAI5060
Yes
Not Provided
Not Provided
Columbia University
Columbia University
Not Provided
Principal Investigator: Ketan K. Badani, M.D. Assistant Professor, Department of Urology, New York Presbyterian Hospital, Columbia University Medical Center
Study Chair: Chris O. Wambi, M.D. Department of Urology, New York Presbyterian Hospital, Columbia University Medical Center
Study Director: Mitchell C. Benson, M.D. Professor and Chairman, Department of Urology, New York Presbyterian Hospital, Columbia University Medical Center
Columbia University
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP